Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Vaccines & Immunizations








Population-Level Risk-Benefit Analysis						Print
																Related Pages
										After use of the Janssen (Johnson & Johnson) COVID-19 vaccine was paused in the U.S., a population-level risk-benefit assessment was conducted to quantify the age-specific risks and benefits of resuming vaccination with this product, including the risk of thrombosis with thrombocytopenia syndrome (TTS), and the benefits of preventing COVID-19-related hospitalizations, intensive care unit (ICU) admissions, and deaths.
The **objectives** of the population-level risk-benefit analysis were to:
Quantify COVID-19 associated hospitalizations, ICU admissions, and deaths averted under different assumptions about the future use of the Janssen COVID-19 Vaccine use.
Quantify population level, age-specific benefits and harms of resuming vaccination with the Janssen COVID-19 vaccine.A compartmental model previously used by the Advisory Committee on Immunization Practices (ACIP) was used for this analysis. This model is stratified by age, essential worker status, and underlying medical condition status and was calibrated to past COVID-19 incidence data through spring 2021 (incidence of COVID-19 cases and hospitalizations available here: https://covid.cdc.gov/covid-data-tracker/#new-hospital-admissions and https://covid.cdc.gov/covid-data-tracker/#trends_dailytrendscases). Future activity was based on the ensemble projection from Round 4 of the multiple model COVID Scenario Modeling Hub (https://covid19scenariomodelinghub.org/index.html and https://github.com/midas-network/covid19-scenario-modeling-hub ) The “Low SARS-CoV-2 transmission”****was calibrated to the Modeling Hub Round 4 Scenario with high vaccination and moderate future compliance to non-pharmaceutical interventions and “Moderate SARS-CoV-2 transmission” was calibrated to the Modeling Hub Round 4 scenario with high vaccination and low future compliance to non-pharmaceutical interventions.
Two types of vaccines were modeled (an mRNA COVID-19 vaccine and the Janssen COVID-19 vaccine); vaccine efficacy estimates were informed by clinical trials1-3 and efficacy was assumed to develop 14 days after administration of each dose (Table 1).Table 1
Vaccine
Vaccine efficacy against infection
Vaccine efficacy against hospitalization or deathmRNA (First Dose)
70%
75%mRNA (Both Doses)
85%
95%J&J/Janssen
65%
90%Additional assumptions in the model included no loss to follow-up with mRNA second doses, no delays in administration of the second dose in the vaccination series, and no waning of immunity from natural infection or vaccination over the 6-month time horizon. Age-group-specific COVID-19 vaccination coverage (https://covid.cdc.gov/covid-data-tracker/#vaccination-demographics-trends ) and intention data through April 2021 (https://www.census.gov/data/tables/2021/demo/hhp/hhp27.html)  were used to project future vaccination coverage. Administration rates for mRNA and Janssen vaccines were based on data from April 6–April 12, 2021 (https://covid.cdc.gov/covid-data-tracker/#vaccination-trends ). ICU admissions were estimated by multiplying the number of hospitalizations estimated by the model by the estimated proportion of hospitalized patients who were admitted to the ICU from the COVID-19 pandemic planning scenarios, available here: www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html. Benefit calculations were evaluated over a 6-month time frame.
Expected numbers of TTS cases were based on confirmed TTS cases, as of April 23rd (Table 2).Table 2. Confirmed TTS cases, Janssen COVID-19 doses administered, and reporting rate, by age and sex
Females
MalesAge group
Cases
Doses admin
Reporting rate
Cases
Doses admin
Reporting rate18–49 years old
13
1,866,294
**7.0** per million
0
1,977,330
**0** per million50+ years old
2
2,125,239
**0.9** per million
0
2,010,144
**0** per millionFive different vaccination scenarios were evaluated, with all scenarios assuming the continued use of mRNA vaccines:
Janssen COVID-19 vaccination not resumed; mRNA vaccine only
Janssen COVID-19 vaccination resumed on April 24 for all adults aged ≥18 years, at 50% of the pre-pause administration rate
Janssen COVID-19 vaccination resumed on April 24 for all adults aged ≥18 years, at 100% of the pre-pause administration rate
Janssen COVID-19 vaccination resumed on April 24 for all adults aged ≥50 years, at 50% of the pre-pause administration rate
Janssen COVID-19 vaccination resumed on April 24 for all adults aged ≥50 years, at 100% of the pre-pause administration rateTable 3 details the results from the population-level benefits and harms scenarios, 6 months post-Janssen COVID-19 vaccine pause, by resumption strategy.  With this approach to assessing risks and benefits, the **benefits of vaccination apply to the entire U.S. adult population over a 6-month period**, and result from both **direct and indirect effects**. Indirect effects are also known as ‘herd protection’ and are based on the assumption that the vaccine can block transmission to unvaccinated persons as well. However, the **risks only pertain to vaccinated persons**.TABLE 3. Population-level estimated number of and percent decrease in COVID-19–related hospitalizations, intensive care unit (ICU) admissions, and deaths after resuming use of Janssen COVID-19 vaccine for 6 months* and number of expected cases of thrombosis with thrombocytopenia syndrome (TTS), by age group and SARS-CoV-2 transmission level† — United States, 2021
Benefits and harms from resuming vaccination
Resumption strategyRecommended for adults aged ≥18 yrs
Recommended for adults aged ≥50 yrsLow SARS-CoV-2 transmission
Moderate SARS-CoV-2 transmission
Low SARS-CoV-2 transmission
Moderate SARS-CoV-2 transmission50% of prepause administration rate**No. of persons expected to receive the Janssen COVID-19 vaccine**
9.8 million
3.6 million**Benefits, no. (% decrease§)**Hospitalizations prevented
3,926 (1.4)
9,395 (1.6)
1,361 (0.5)
3,532 (0.6)ICU admissions prevented
928 (1.4)
2,236 (1.5)
295 (0.4)
799 (0.5)Deaths prevented
586 (1.6)
1,435 (1.8)
54 (0.1)
257 (0.3)**Harms**No. of TTS cases expected
26
26
2
2100% of prepause administration rate**No. of persons expected to receive the Janssen COVID-19 vaccine**
17.5 Million
5.9 Million**Benefits, no. (% decrease§)**Hospitalizations prevented
5,987 (2.2%)
14,771 (2.5%)
1,947 (0.7%)
4,522 (0.7%)ICU admissions prevented
1,418 (2.1%)
3,517 (2.4%)
396 (0.6%)
953 (0.6%)Deaths prevented
882 (2.4%)
2,226 (2.8%)
43 (0.1%)
208 (0.3%)**Harms**No. of TTS cases expected
45
45
3
3**Abbreviations:** ICU = intensive care unit; TTS = thrombosis with thrombocytopenia syndrome.
* Resumption of vaccination after a 10-day pause that commenced on April 13, 2021 https://emergency.cdc.gov/han/2021/han00442.asp
† This model evaluated the direct and indirect effects of resuming 50% or 100% of Janssen COVID-19 administration rates (compared with rate before use was paused) among all adults aged ≥18 years or only among adults ≥50 years compared with not resuming vaccination. The model was also calibrated to both low and moderate COVID-19 transmission levels based on varying assumptions about nonpharmaceutical interventions during the modeled time period.
§ Compared with no resumption of Janssen vaccination.Individual-Level Risk-Benefit Analysis
An individual-level risk-benefit assessment was conducted to quantify age and sex-specific benefits and harms, per million Janssen vaccine doses.
The **objectives** of the individual-level risk-benefit analysis were to:
Quantify COVID-19-associated hospitalizations, ICU admissions, and deaths averted among vaccinated persons per million doses of the Janssen COVID-19 vaccine used, by age group and sex, and
Compare these benefits to the expected numbers of TTS cases in the same population groups.Calculations were based on:
Recent age-specific incidence of hospitalizations for COVID-19 from COVID-NET
Week ending March 27, 2021
Age groups 18–29, 30–49 (averaged from 30–39 and 40–49), 50–64, ≥65 years
Overall hospitalization rates, (weekly incidence of 7.9 per 100,000 population), one location with higher weekly incidence (17.8 per 100,000), and one location with lower weekly incidence (2.6 per 100,000)
Proportions of hospitalized COVID-19 patients admitted to ICU or who died
Number of persons already vaccinated as of April 21, 2021
Expected TTS cases, based on estimated rates of TTS as of April 24, 2021, Table 1. One case of TTS in a male clinical trial participant in the 18–49 year age group was included4. The denominator was not adjusted for doses received during Phase III trial because they were not available in the specified age groups; however, the numbers are small relative to the numbers administered post authorization.
90% efficacy of Janssen COVID-19 vaccine to prevent hospitalizations from COVID-193.
Additional simplifying assumptions: All unvaccinated persons have equal age-specific risk of hospitalization due to COVID-19 and all incident cases were considered to be in unvaccinated persons.Details on COVID-NET methods are available here. COVID-NET is a population-based surveillance system that collects data on laboratory-confirmed COVID-19-associated hospitalizations among children and adults through a network of over 250 acute-care hospitals in 14 states. Hospitalization rates are calculated by the number of residents of a defined area who are hospitalized with a positive SARS-CoV-2 laboratory test divided by the total population within that defined area. Calculations were based on data available through April 20, 2021.
The calculations assume a 30-day period at risk as a result of delay in receiving an alternative COVID-19 vaccine, if the Janssen COVID-19 vaccine was not available, compared to not receiving any COVID-19 vaccine for this period of time. Analyses were also conducted to evaluate 60-day and 120-day delays in vaccination, and lower and higher incidence.
The individual-level risk-benefit analysis could be adapted to different incidence situations and with different assumptions about the lag in vaccination if the Janssen COVID-19 vaccine is not available. Table 4 details the results from the individual-level benefits and harms scenarios, 30, 60, and 120 days post-Janssen COVID-19 vaccine pause, by age and sex.  With this approach to assessing risks and benefits, the benefits and risks of vaccination apply during the**time period where there may be a delay in receipt of a COVID-19 vaccine**, if a Janssen COVID-19 vaccine is not available. In addition, the risks and benefits both **apply** **directly to the vaccinated person**.TABLE 4. Individual-level estimated number of COVID-19–related hospitalizations, ICU admissions, and deaths prevented after resuming use of Janssen COVID-19 vaccine* and number of expected cases of thrombosis with thrombocytopenia syndrome per 1 million vaccine doses, by sex and age group, with varying incidence and timing scenarios† — United States, 2021
Benefits and harms from resuming vaccination
No. per million vaccine doses administered§Females
Males18–49 yrs
≥50 yrs
18–49 yrs¶
≥50 yrsHarmsTTS cases expected
7
1
1
0Benefits, 30d, overall incidence‖Hospitalizations prevented
297
2,454
272
2,821ICU admissions prevented
56
661
51
760Deaths prevented
6
394
6
471Benefits, 30d, low U.S. state incidence‖Hospitalizations prevented
106
698
97
786ICU admissions prevented
20
188
18
212Deaths prevented
2
107
2
127Benefits, 30d, high U.S. state incidence‖Hospitalizations prevented
580
5766
530
6644ICU admissions prevented
110
1554
100
1790Deaths prevented
12
929
11
1113Benefits, 60d, overall incidence‖Hospitalizations prevented
594
4908
544
5642ICU admissions prevented
112
1323
103
1520Deaths prevented
12
787
11
942Benefits, 120d, overall incidence‖Hospitalizations prevented
1189
9816
1087
11285ICU admissions prevented
225
2645
206
3040Deaths prevented
25
1574
23
1884**Abbreviations:** ICU = intensive care unit; TTS = thrombosis with thrombocytopenia syndrome.
* Resumption of vaccination after a 10-day pause that began on April 13, 2021. https://emergency.cdc.gov/han/2021/han00442.asp
† This analysis evaluated direct benefits and harms, per 1 million Janssen COVID-19 vaccine doses, over 30, 60, or 120 days.
§ Compared with no resumption of Janssen vaccination.
¶ Analyses incorporated one TTS case that occurred in the Phase III trial in a man in the 18–49 years age group.
‖ Incidence of hospitalization for week ending March 27, 2021, obtained from https://gis.cdc.gov/grasp/COVIDNet/COVID19_3.htmlSummary
The population- and individual-level approaches to risk-benefit analyses offer complementary information on the risks and benefits of resuming vaccination, and in which age groups.
The population approach takes into account direct and indirect (herd) effects of vaccination, incorporates availability of different vaccines, simulates hospitalizations, ICU admissions and deaths under different transmission scenarios, and makes estimations of all outcomes over a 6-month time horizon. This approach shows a large population benefit of Janssen vaccination relative to rare occurrence of TTS.
The direct individual level approach estimates benefits and risks to vaccinated individuals, and only considers getting Janssen vaccine compared to not getting any vaccine over a short, 30-day time horizon. The analysis showed a positive balance of benefits and risks for all age and sex groups. However, the relative balance of risks and benefits for individuals varies by age and sex because cases of TTS were primarily identified among women aged 18–49 years. Benefits are higher when incidence (i.e., risk of exposure) is higher and when the assumed delay in vaccination is greater.
References:
Oliver S, Gargano J, Marin M, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020. MMWR Morb Mortal Wkly Rep 2020;69:1922-1924. DOI: http://dx.doi.org/10.15585/mmwr.mm6950e2
Oliver S, Gargano J, Marin M, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020. MMWR Morb Mortal Wkly Rep 2021;69:1653-1656. DOI: http://dx.doi.org/10.15585/mmwr.mm695152e1
Oliver SE, Gargano JW, Scobie H, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021. MMWR Morb Mortal Wkly Rep 2021;70:329–332. DOI: http://dx.doi.org/10.15585/mmwr.mm7009e4
Vaccines and Related Biological Products Advisory Committee. Vaccines and Related Biological Products Advisory Committee February 26, 2021, meeting: FDA briefing document. Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration; 2021. https://www.fda.gov/media/146217/downloadTop of Page
							
					
							Last Reviewed:  August 20, 2021						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeCOVID-19 Vaccination
Product Info by U.S. Vaccineplus icon
EUA
EUI
Interim Clinical Considerationsplus icon
Use of COVID-19 Vaccines in the U.S.
Use of COVID-19 Vaccines in the U.S.: Appendices
FAQs for the Interim Clinical Considerations
Myocarditis and Pericarditis Considerations
Clinical Care
Provider Requirements and Support
Vaccine Recipient Educationplus icon
Talking with Patients about COVID-19 Vaccination
How to Tailor COVID-19 Information to Your Audience
How to Address COVID-19 Vaccine Misinformation
Health Departments
Planning & Partnerships
6 Things to Know
Equity in Childhood COVID-19 Vaccination
COVID-19 Vaccine Data Systemsplus icon
Overviewplus icon
Vaccine IT Overview
Data Reporting Requirements
Vaccine Administration Management System (VAMS)plus icon
Getting Started in VAMS
General Public User
Resources for Jurisdictions, Clinics, and Organizations
VAMS Program Information
Vaccinate with Confidenceplus icon
What Is Vaccine Confidence?
Vaccine Confidence Strategies
Rapid Community Assessment Guide
COVID-19 Vaccine Confidence Data
12 COVID-19 Vaccination Strategies for Your Community
How to Engage the Arts to Build COVID-19 Vaccine Confidence
Strategies for Reaching People with Limited Access to COVID-19 Vaccines


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue